Research Focus

Former Employee. GRADUATE STAFF; NE Rotating Housestaff

Recent additions – View all

1. Inotuzumab ozogamicin is an effective salvage therapy in relapsed/refractory B-cell acute lymphoblastic leukemia with high-risk molecular features, including TP53 loss

   Meeting Abstract

   Yang, X.; King, A. C.; Kabel, C. C.; Forlenza, C. J.; Park, J. H.; Geyer, M. B.
   Blood (2019)

   Fulltext@MSK | Save
2. Inotuzumab ozogamicin as chemotherapy-sparing salvage in a 67-year-old man with primary refractory B-cell acute lymphoblastic leukemia with high-risk genomic features

   Journal Article

   Yang, X.; Sen, F.; Geyer, M. B.
   Leukemia Research Reports (2019)

   Fulltext@MSK | Save